Literature DB >> 2292700

Cyclosporin-associated akinetic mutism and extrapyramidal syndrome after liver transplantation.

G L Bird1, J Meadows, J Goka, R Polson, R Williams.   

Abstract

Three patients developed akinetic mutism on the third day after the introduction of intravenous cyclosporin A, given for immunosuppression after liver transplantation. One patient in addition developed a florid orofacial dyskinesia, which resolved completely, as did the akinetic mutism, after withdrawal of cyclosporin. In these patients the time course of the akinetic mutism and extrapyramidal syndrome, which developed in the absence of any other identifiable cause, suggests cyclosporin A was the precipitating factor. Subsequently, two of the patients showed signs of pseudobulbar palsy with abnormalities in the pons on MRI scanning, suggesting central pontine myelinolysis (CPM). None of the patients had experienced significant fluctuations in serum sodium or other risk factors for central pontine myelinolysis and the exact relationship to the earlier cyclosporin related mutism was not clear.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292700      PMCID: PMC488317          DOI: 10.1136/jnnp.53.12.1068

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Magnetic resonance imaging in central pontine myelinolysis.

Authors:  P D Thompson; D Miller; R F Gledhill; M N Rossor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

2.  The etiology of seizures after cardiac transplantation.

Authors:  M M Grigg; M R Costanzo-Nordin; G G Celesia; M A Kelly; M A Silver; P A Sobotka; J A Robinson
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

3.  Cyclosporine-associated encephalopathy in childhood transplant patients.

Authors:  B Lavenstein; C Stewart; L U Tina
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

4.  Akinesia and mutism following a methylphenidate challenge test.

Authors:  J Wiener; S Kennedy
Journal:  J Clin Psychopharmacol       Date:  1985-08       Impact factor: 3.153

5.  Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol.

Authors:  P C de Groen; A J Aksamit; J Rakela; G S Forbes; R A Krom
Journal:  N Engl J Med       Date:  1987-10-01       Impact factor: 91.245

6.  Akinetic mutism in a bone marrow transplant recipient following total-body irradiation and amphotericin B chemoprophylaxis. A positron emission tomographic and neuropathologic study.

Authors:  O Devinsky; W Lemann; A C Evans; J R Moeller; D A Rottenberg
Journal:  Arch Neurol       Date:  1987-04

7.  Cerebral blindness and encephalopathy with cyclosporin A toxicity.

Authors:  A M Rubin; H Kang
Journal:  Neurology       Date:  1987-06       Impact factor: 9.910

8.  Central pontine myelinolysis after liver transplantation.

Authors:  C J Estol; A A Faris; A J Martinez; M Ahdab-Barmada
Journal:  Neurology       Date:  1989-04       Impact factor: 9.910

9.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA.

Authors:  M R Lucey; J C Kolars; R M Merion; D A Campbell; M Aldrich; P B Watkins
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

  9 in total
  11 in total

1.  Delusions and cyclosporine toxicity.

Authors:  J V Bowler; R C Peatfield
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

2.  Akinetic mutism followed by a manic reaction on introduction of steroid replacement for Addison's disease.

Authors:  G Kalambokis; S Konitsiotis; D Pappas; E V Tsianos
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

3.  Neurologic complications of FK 506.

Authors:  B H Eidelman; K Abu-Elmagd; J Wilson; J J Fung; M Alessiani; A Jain; S Takaya; S N Todo; A Tzakis; D Van Thiel
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Chronic administration of cyclosporine A changes expression of BDNF and TrkB in rat hippocampus and midbrain.

Authors:  Chien-Chih Chen; Li-Wen Hsu; Li-Tung Huang; Tiao-Lai Huang
Journal:  Neurochem Res       Date:  2010-04-02       Impact factor: 3.996

5.  Central pontine myelinolysis following orthotopic liver transplant: association with cyclosporine toxicity.

Authors:  M H Kabeer; R S Filo; M L Milgrom; M D Pescovitz; S B Leapman; L Lumeng; R M Jindal
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

6.  Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors.

Authors:  C de Brabander; J Cornelissen; P A Smitt; C J Vecht; M J van den Bent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-01       Impact factor: 10.154

7.  Identifying risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a case-control study.

Authors:  Isabelle Morard; Yvan Gasche; Mark Kneteman; Christian Toso; Ariane Mentha; Glenda Meeberg; Gilles Mentha; Norman Kneteman; Emiliano Giostra
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

8.  Possible causes of central pontine myelinolysis after liver transplantation.

Authors:  Jun Yu; Shu-Sen Zheng; Ting-Bo Liang; Yan Shen; Wei-Lin Wang; Qing-Hong Ke
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

9.  Rapid Response of Long-Standing, Treatment-Resistant Non-Catatonic Mutism in Paranoid Schizophrenia with Single ECT session.

Authors:  Mansoor Ahmad Dar; Yasir Hassan Rather; Majid Shafi Shah; Rayees Ahmad Wani; Arshad Hussain
Journal:  N Am J Med Sci       Date:  2014-11

10.  Drug-resistant epilepsy development following stem cell transplant and cyclosporine neurotoxicity induced seizures: Case report in an adult and analysis of reported cases in the literature.

Authors:  Adam S Vesole; Yasunori Nagahama; Mark A Granner; Matthew A Howard; Hiroto Kawasaki; Brian J Dlouhy
Journal:  Epilepsy Behav Case Rep       Date:  2018-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.